Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?

Nature Clinical Practice Oncology volume 3, pages 200–213 (2006)Cite this article

Abstract

Defining rational follow-up guidelines in patients treated for cancer is important, from both a medical and an economical perspective. Renal-cell carcinoma is reputed to be unpredictable in its course and only a few, and often contradictory, follow-up guidelines exist for patients treated for nonmetastatic renal-cell carcinoma. Recent advances in tumor biology have contributed to a better understanding of this cancer and have indicated that personalized follow-up regimens, based on tumor and host molecular characteristics, might be possible in the near future.

Key Points

  • Conventional prognostic factors (e.g. TNM stage, histological subtype and grade) are robust parameters with appropriate validation but cannot entirely explain the complex natural history of renal-cell carcinoma

  • Comprehensive nomograms that combine recognized outcome predictors seem to dramatically improve recurrence prognostication and should be widely used in the near future

  • Many promising molecular markers with prognostic value have been described, but further validation is needed before they can be used in clinical practice

  • Metastases usually appear within 2 years after radical nephrectomy, but 9–11% of the patients surviving at 10 years will experience late recurrence

  • The promising preliminary results obtained with antiangiogenic treatments emphasize the need for early identification of recurrence and thus for rational follow-up protocols

  • It is hoped that prognostic nomograms combining conventional and molecular markers will help to customize the follow-up strategy to the actual risk of recurrence for each patient

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Javidan J et al. (1999) Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 162: 1277–1281

    Article  CAS  PubMed  Google Scholar 

  2. Frank I et al. (2003) A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 170: 2225–2232

    Article  PubMed  Google Scholar 

  3. Lam JS et al. (2005) Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174: 466–472

    Article  PubMed  Google Scholar 

  4. Ljungberg B et al. (1999) Follow up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84: 405–411

    Article  CAS  PubMed  Google Scholar 

  5. Méjean A et al. (2003) Prognostic factors of renal cell carcinoma. J Urol 169: 821–827

    Article  PubMed  Google Scholar 

  6. Goncalves PD et al. (2004) Low clinical stage renal cell carcinoma: relevance of microvascular tumor invasion as a prognostic parameter. J Urol 172: 470–474

    Article  PubMed  Google Scholar 

  7. Patard JJ et al. (2004) Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 172: 858–862

    Article  PubMed  Google Scholar 

  8. Frank I et al. (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168: 2395–2400

    Article  PubMed  Google Scholar 

  9. Leibovich BC et al. (2003) Current staging of renal cell carcinoma. Urol Clin N Am 30: 481–497

    Article  Google Scholar 

  10. Han KR et al. (2003) TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 169: 899–904

    Article  PubMed  Google Scholar 

  11. Siemer S et al. (2005) Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173: 33–37

    Article  CAS  PubMed  Google Scholar 

  12. Delahunt B et al. (2002) Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma. Cancer 94: 658–664

    Article  PubMed  Google Scholar 

  13. Eschwege P et al. (1996) Radical nephrectomy for renal cell carcinoma 30 mm or less: long term follow-up results. J Urol 155: 1196–1199

    Article  CAS  PubMed  Google Scholar 

  14. McNichols DW et al. (1981) Renal cell carcinoma: long-term survival and late recurrence. J Urol 126: 17–23

    Article  CAS  PubMed  Google Scholar 

  15. Kim HL et al. (2004) Prognostic significance of venous thrombus in renal cell carcinoma: are renal vein and inferior vena cava involvement different? J Urol 171: 588–591

    Article  PubMed  Google Scholar 

  16. Lam JS et al. (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173: 1853–1862

    Article  PubMed  Google Scholar 

  17. Bonsib SM et al. (2000) Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 24: 451–458

    Article  CAS  PubMed  Google Scholar 

  18. Van Poppel H et al. (1997) Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol 158: 45–49

    Article  CAS  PubMed  Google Scholar 

  19. Yildiz E et al. (2004) Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int 93: 1087–1093

    Article  CAS  PubMed  Google Scholar 

  20. Palapattu GS et al. (2003) Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol 170: 768–772

    Article  PubMed  Google Scholar 

  21. Amin MB et al. (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms. Am J Surg Pathol 26: 281–291

    Article  PubMed  Google Scholar 

  22. Medeiros LJ et al. (1997) Grading of renal cell carcinoma: Workgroup No. 2. Union Internationale Contre le Cancer and the American Joint Committee on Cancer (AJCC). Cancer 80: 990–991

    Article  CAS  PubMed  Google Scholar 

  23. Cheville JC et al. (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612–624

    Article  PubMed  Google Scholar 

  24. Fujikawa K et al. (1997) Role of volume weighted mean nuclear volume for predicting disease outcome in patients with renal cell carcinoma. J Urol 157: 1237–1241

    Article  CAS  PubMed  Google Scholar 

  25. Ruiz JL et al. (1995) Value of morphometry as an independent prognostic factor in renal cell carcinoma. Eur Urol 27: 54–57

    Article  CAS  PubMed  Google Scholar 

  26. Carducci MA et al. (1999) Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 53: 44–49

    Article  CAS  PubMed  Google Scholar 

  27. Eble JN et al. (2004) World Health Organization Classification of Tumours: Pathology & Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press

    Google Scholar 

  28. Cheville JC et al. (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28: 435–441

    Article  PubMed  Google Scholar 

  29. Moch H et al. (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89: 604–614

    Article  CAS  PubMed  Google Scholar 

  30. Patard JJ et al. (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 20: 2763–2771

    Article  Google Scholar 

  31. Renshaw AA and Richie JP (1999) Subtypes of renal cell carcinoma: different onset and sites of metastatic disease. Am J Clin Pathol 111: 539–543

    Article  CAS  PubMed  Google Scholar 

  32. Jiang F et al. (1998) Chromosomal imbalances in papillary renal cell carcinoma. Am J Pathol 153: 1467–1473

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Imao T et al. (2004) Inverse correlation of microvessel density with metastasis and prognosis in renal cell carcinoma. Int J Urol 11: 948–953

    Article  PubMed  Google Scholar 

  34. Rioux-Leclercq N et al. (2001) Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 32: 1209–1215

    Article  CAS  PubMed  Google Scholar 

  35. Lam JS et al. (2005) Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 103: 2517–2525

    Article  CAS  PubMed  Google Scholar 

  36. Zisman A et al. (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19: 1649–1657

    Article  CAS  PubMed  Google Scholar 

  37. Kim HL et al. (2003) Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 170: 1742–1746

    Article  PubMed  Google Scholar 

  38. Kattan MW et al. (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166: 63–67

    Article  CAS  PubMed  Google Scholar 

  39. Murphy N et al. (2005) Gene expression profiling in breast cancer: towards individualising patient management. Pathology 37: 271–277

    Article  CAS  PubMed  Google Scholar 

  40. Ami Y et al. (2005) Gene expression profiles correlate with the morphology and metastasis characteristics of renal cell carcinoma cells. Oncol Rep 13: 75–80

    CAS  PubMed  Google Scholar 

  41. Ransohoff DF (2005) Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5: 142–149

    Article  CAS  PubMed  Google Scholar 

  42. Ljungberg B et al. (1996) Heterogeneity in renal cell carcinoma and its impact no prognosis—a flow cytometric study. Br J Cancer 74: 123–127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ruiz-Cerda JL et al. (1996) Value of deoxyribonucleic acid ploidy and nuclear morphometry for prediction of disease progression in renal cell carcinoma. J Urol 155: 459–465

    Article  CAS  PubMed  Google Scholar 

  44. Di Silverio F et al. (2000) Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer 88: 835–843

    Article  CAS  PubMed  Google Scholar 

  45. Chautard D et al. (2004) Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. Urology 63: 1055–1060

    Article  PubMed  Google Scholar 

  46. Schullerus D et al. (1997) Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 183: 151–155

    Article  CAS  PubMed  Google Scholar 

  47. Presti JC et al. (2002) Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 167: 1464–1468

    Article  CAS  PubMed  Google Scholar 

  48. Velickovic M et al. (2002) Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 15: 479–485

    Article  PubMed  Google Scholar 

  49. Schraml P et al. (2000) Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma. J Pathol 190: 457–461

    Article  CAS  PubMed  Google Scholar 

  50. Visapaa H et al. (2003) Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 61: 845–850

    Article  PubMed  Google Scholar 

  51. Hedberg Y et al. (2003) Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 88: 1417–1423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Rioux-Leclercq N et al. (2004) Immunohistochemical analysis of tumor polyamines discriminates high-risk patients undergoing nephrectomy for renal cell carcinoma. Hum Pathol 35: 1279–1284

    Article  CAS  PubMed  Google Scholar 

  53. Parker AS et al. (2002) High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal carcinomas. Hum Pathol 33: 801–805

    Article  CAS  PubMed  Google Scholar 

  54. Miyake H et al. (2002) Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J Urol 167: 703–706

    Article  CAS  PubMed  Google Scholar 

  55. Kim HL et al. (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10: 5464–5471

    Article  CAS  PubMed  Google Scholar 

  56. Sulzbacher I et al. (2003) Expression of platelet-derived growth factor-α–α receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120: 107–112

    Article  CAS  PubMed  Google Scholar 

  57. Langner C et al. (2004) Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol 171: 611–614

    Article  CAS  PubMed  Google Scholar 

  58. Pavlovich CP and Schmidt LS (2004) Searching for the hereditary causes of renal cell carcinoma. Nat Rev Cancer 4: 381–393

    Article  CAS  PubMed  Google Scholar 

  59. Lam JS et al. (2004) Tissue-array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin Cancer Res 10: 6304S–6309S

    Article  CAS  PubMed  Google Scholar 

  60. Bui M et al. (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802–811

    CAS  PubMed  Google Scholar 

  61. Bui MH et al. (2004) Prognostic value of carbonic anhydrase ix and Ki-67 as predictors of survival for renal clear cell carcinoma. J Urol 171: 2461–2466

    Article  PubMed  Google Scholar 

  62. Yao M et al. (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Nat Cancer Inst 94: 1569–1575

    Article  CAS  PubMed  Google Scholar 

  63. Shimazui T et al. (1997) Decreased expression of α-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer 74: 523–528

    Article  CAS  PubMed  Google Scholar 

  64. Seligson DB et al. (2004) Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10: 2659–2669

    Article  CAS  PubMed  Google Scholar 

  65. Daniel L et al. (2003) Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Hum Pathol 34: 528–532

    Article  CAS  PubMed  Google Scholar 

  66. Cho NM et al. (2003) Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 44: 560–566

    Article  CAS  PubMed  Google Scholar 

  67. Ikemoto S et al. (2003) Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep 10: 1843–1849

    CAS  PubMed  Google Scholar 

  68. Banner BF et al. (1990) Immunophenotypic markers in renal cell carcinoma. Mod Pathol 3: 129–134

    CAS  PubMed  Google Scholar 

  69. Nakano O et al. (2001) Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61: 5132–5136

    CAS  PubMed  Google Scholar 

  70. Bromwich EJ et al. (2003) The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 89: 1906–1908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Hemmerlein B et al. (2000) Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas. Cancer Immunol Immunother 19: 485–492

    Article  Google Scholar 

  72. Thompson RH et al. (2005) Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 15: 2084–2091

    Article  CAS  Google Scholar 

  73. Dosquet C et al. (1997) Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 3: 2451–2458

    CAS  PubMed  Google Scholar 

  74. Grankvist K et al. (1997) Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int J Cancer 74: 233–236

    Article  CAS  PubMed  Google Scholar 

  75. Gonzalgo ML et al. (2002) Prognostic significance of preoperative molecular serum analysis in renal cancer. Clin Cancer Res 8: 1878–1881

    CAS  PubMed  Google Scholar 

  76. Junker K et al. (2005) CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 173: 2150–2153

    Article  CAS  PubMed  Google Scholar 

  77. Zisman A et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559–4566

    Article  PubMed  Google Scholar 

  78. Patard JJ et al. (2004) Use of the University of California Los Angeles Integrated Staging System to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 15: 3316–3322

    Article  Google Scholar 

  79. Saitoh H (1982) Distant metastasis of renal adenocarcinoma in nephrectomized cases. J Urol 127: 1092–1095

    Article  CAS  PubMed  Google Scholar 

  80. Sandock DS et al. (1995) A new protocol for the follow up of renal cell carcinoma based on pathological stage. J Urol 154: 28–31

    Article  CAS  PubMed  Google Scholar 

  81. Beisland C et al. (2004) Presumed radically treated renal cell carcinoma. Scand J Urol Nephrol 38: 299–305

    Article  PubMed  Google Scholar 

  82. Stephenson AJ et al. (2004) Guidelines for the surveillance of localized renal-cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172: 58–62

    Article  PubMed  Google Scholar 

  83. Montie JE (1994) Follow up after partial or total nephrectomy for renal cell carcinoma. Urol Clin N Am 21: 589–592

    CAS  Google Scholar 

  84. O'Dea MJ et al. (1978) The treatment of renal cell carcinoma with solitary metastasis. J Urol 120: 540–542

    Article  CAS  PubMed  Google Scholar 

  85. Itano NB et al. (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164: 322–325

    Article  CAS  PubMed  Google Scholar 

  86. Dineen MK et al. (1988) Results of surgical treatment of renal cell carcinoma with solitary metastasis. J Urol 140: 277–279

    Article  CAS  PubMed  Google Scholar 

  87. Kanamaru H et al. (1997) Histologic characteristics of renal cell carcinomas with lymph node metastasis. Int J Urol 4: 451–455

    Article  CAS  PubMed  Google Scholar 

  88. Stacker SA et al. (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186–191

    Article  CAS  PubMed  Google Scholar 

  89. Minn AJ et al. (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115: 44–55

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Roepman P et al. (2005) An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37: 182–186

    Article  CAS  PubMed  Google Scholar 

  91. Rabbani F et al. (2002) Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. J Clin Oncol 20: 2370–2375

    Article  PubMed  Google Scholar 

  92. Budin RE and McDonnel PJ (1984) Renal cell neoplasms. Arch Pathol Lab Med 108: 138–140

    CAS  PubMed  Google Scholar 

  93. Hafez KS et al. (1997) Patterns of tumor recurrence and guidelines for follow up after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 157: 2067–2070

    Article  CAS  PubMed  Google Scholar 

  94. Novick AC (1995) Partial nephrectomy for renal cell carcinoma. Urology 46: 149–152

    Article  CAS  PubMed  Google Scholar 

  95. Patard JJ et al. (2004) Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171: 2181–2185

    Article  PubMed  Google Scholar 

  96. Levy DA et al. (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159: 1163–1167

    Article  CAS  PubMed  Google Scholar 

  97. Swanson DA (2004) Surgery for metastases of renal cell carcinoma. Scan J Surg 93: 150–155

    Article  CAS  Google Scholar 

  98. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80: 1198–1220

    Article  CAS  PubMed  Google Scholar 

  99. Yang JC et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127–3132

    Article  CAS  PubMed  Google Scholar 

  100. Négrier S et al. (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 13: 1460–1468

    Article  PubMed  Google Scholar 

  101. Négrier S et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272–1278

    Article  PubMed  Google Scholar 

  102. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Escudier B et al. (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma [abstract #4510]. J Clin Oncol 23 (Suppl): aS1093

    Google Scholar 

  104. Motzer RJ et al. (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma [abstract #4508]. J Clin Oncol 23 (Suppl): aS380

    Google Scholar 

  105. Rini BI et al. (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer [abstract #4509]. J Clin Oncol 23 (Suppl): aS380

    Google Scholar 

  106. Mukouyama H et al. (2004) Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res 10: 1421–1429

    Article  CAS  PubMed  Google Scholar 

  107. Henriksson C et al. (1992) Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scand J Urol Nephrol 26: 363–366

    Article  CAS  PubMed  Google Scholar 

  108. Marshall ME et al. (1990) Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. Urology 36: 300–302

    Article  CAS  PubMed  Google Scholar 

  109. Méjean A et al. (2002) Tumeurs du rein. Prog Urol 12 (Suppl 2): S9–S14

    Google Scholar 

  110. Gofrit ON et al. (2001) Renal cell carcinoma: evaluation of the 1997 TNM system and recommendations for follow-up after surgery. Eur Urol 39: 669–675

    Article  CAS  PubMed  Google Scholar 

  111. Rehman S and Jayson GC (2005) Molecular imaging of antiangiogenic agents. Oncologist 10: 92–103

    Article  CAS  PubMed  Google Scholar 

  112. Laking GR et al. (2006) Imaging vascular physiology to monitor cancer treatment. Crit Rev Onc Hematol [doi: 10.1016/j.critrevonc.2005.10.006]

Download references

Author information

Authors and Affiliations

  1. Senior Radiologist in the Department of Urinary, Vascular and Interventional Radiology at the Edouard Herriot Hospital, and Researcher in Unit 556 of the Institut National de la Santé et de la Recherche Médicale (INSERM), Lyon, France

    Olivier Rouvière

  2. Head of the Department of Urologic Pathology,

    Raymonde Bouvier, Sylvie Négrier, Lionel Badet & Denis Lyonnet

  3. Deputy Director at the Léon Bérard Comprehensive Cancer Center,

    Raymonde Bouvier, Sylvie Négrier, Lionel Badet & Denis Lyonnet

  4. Assistant Professor of Urology and Transplant Surgery,

    Raymonde Bouvier, Sylvie Négrier, Lionel Badet & Denis Lyonnet

  5. Head of the Department of Urinary, Vascular and Interventional Radiology, Edouard Herriot Hospital, Lyon, France

    Raymonde Bouvier, Sylvie Négrier, Lionel Badet & Denis Lyonnet

Authors
  1. Olivier Rouvière
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymonde Bouvier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvie Négrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lionel Badet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Denis Lyonnet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivier Rouvière.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rouvière, O., Bouvier, R., Négrier, S. et al. Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?. Nat Rev Clin Oncol 3, 200–213 (2006). https://doi.org/10.1038/ncponc0479

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0479

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing